

Alfredo Papa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4400252/publications.pdf>

Version: 2024-02-01

130
papers

4,974
citations

87888

38
h-index

98798

67
g-index

130
all docs

130
docs citations

130
times ranked

6442
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study. <i>American Journal of Gastroenterology</i> , 2010, 105, 2218-2227.	0.4	390
2	Extraintestinal manifestations in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2005, 11, 7227.	3.3	358
3	Inflammation and Coagulation in Inflammatory Bowel Disease: The Clot Thickens. <i>American Journal of Gastroenterology</i> , 2007, 102, 174-186.	0.4	322
4	Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. <i>Gut</i> , 2003, 52, 1435-1441.	12.1	223
5	Role and mechanisms of action of <i>Escherichia coli</i> Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update. <i>World Journal of Gastroenterology</i> , 2016, 22, 5505.	3.3	141
6	Homocysteine Triggers Mucosal Microvascular Activation in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2005, 100, 886-895.	0.4	119
7	Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 769-779.	1.3	114
8	Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 664-684.	3.7	102
9	Increased carotid intima-media thickness in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 839-846.	3.7	97
10	Review Article: Inherited Thrombophilia in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2003, 98, 1247-1251.	0.4	95
11	Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 880-888.	3.7	94
12	Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 2677-2682.	0.4	88
13	Adhesion molecules in inflammatory bowel disease: Therapeutic implications for gut inflammation. <i>Digestive and Liver Disease</i> , 2005, 37, 811-818.	0.9	88
14	Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti-TNF- α agents: Effects of combined therapy with immunosuppressants. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 301-307.	1.3	86
15	Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: An open-label pilot study. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e623-e629.	1.3	85
16	Inter-observer agreement in endoscopic scoring systems: Preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2014, 46, 969-973.	0.9	78
17	Anti TNF- α therapy for ulcerative colitis: current status and prospects for the future. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 223-233.	3.0	78
18	Ileal Crohn Disease: Mural Microvascularity Quantified with Contrast-enhanced US Correlates with Disease Activity. <i>Radiology</i> , 2012, 262, 680-688.	7.3	74

#	ARTICLE	IF	CITATIONS
19	Can We Predict the Efficacy of Anti-TNF- $\hat{\pm}$ Agents?. International Journal of Molecular Sciences, 2017, 18, 1973.	4.1	73
20	Potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2000, 14, 1403-1409.	3.7	68
21	Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor- $\hat{\pm}$ agents. Journal of Crohn's and Colitis, 2013, 7, 113-119.	1.3	68
22	Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. International Journal of Colorectal Disease, 2011, 26, 1435-1444.	2.2	66
23	Infliximab in Steroid-dependent Ulcerative Colitis. Inflammatory Bowel Diseases, 2013, 19, 1065-1072.	1.9	66
24	Role of Dental Plaque in the Transmission of Helicobacter Pylori Infection. Journal of Clinical Gastroenterology, 1996, 22, 174-177.	2.2	65
25	Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor $\hat{\pm}$ agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. Digestive and Liver Disease, 2014, 46, 974-979.	0.9	64
26	Venous thromboembolism in patients with inflammatory bowel disease: Focus on prevention and treatment. World Journal of Gastroenterology, 2014, 20, 3173.	3.3	63
27	Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)- $\hat{\pm}$ on the Liver. International Journal of Molecular Sciences, 2018, 19, 2199.	4.1	62
28	Vascular Involvement in Inflammatory Bowel Disease: Pathogenesis and Clinical Aspects. Digestive Diseases, 2008, 26, 149-155.	1.9	60
29	SARS-CoV2 RNA detection in a pancreatic pseudocyst sample. Pancreatology, 2020, 20, 1011-1012.	1.1	59
30	International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 857-873.	17.8	56
31	Long-term Combination Therapy with Infliximab Plus Azathioprine Predicts Sustained Steroid-free Clinical Benefit in Steroid-dependent Ulcerative Colitis. Inflammatory Bowel Diseases, 2014, 20, 1368-1374.	1.9	55
32	Prevention and Treatment of Low-grade B-cell Primary Gastric Lymphoma by Anti-H. Pylori Therapy. Journal of Clinical Gastroenterology, 1995, 21, 118-122.	2.2	53
33	Characterization of Sarcopenia in an IBD Population Attending an Italian Gastroenterology Tertiary Center. Nutrients, 2019, 11, 2281.	4.1	47
34	COVID-19 infection in Crohn's disease under treatment with adalimumab. Gut, 2020, 69, 1364-1365.	12.1	46
35	Helicobacter pylori CagA-positive Strains Affect Oxygen Free Radicals Generation by Gastric Mucosa. Scandinavian Journal of Gastroenterology, 2001, 36, 247-250.	1.5	45
36	Differentiation Affects the Release of Exosomes from Colon Cancer Cells and Their Ability to Modulate the Behavior of Recipient Cells. American Journal of Pathology, 2017, 187, 1633-1647.	3.8	42

#	ARTICLE	IF	CITATIONS
37	Role of Helicobacter pylori CagA + Infection in Determining Oxidative DNA Damage in Gastric Mucosa. Scandinavian Journal of Gastroenterology, 2002, 37, 409-413.	1.5	41
38	COVID-19 and intestinal inflammation: Role of fecal calprotectin. Digestive and Liver Disease, 2020, 52, 1231-1233.	0.9	40
39	Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre. United European Gastroenterology Journal, 2020, 8, 775-781.	3.8	40
40	Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: a single-centre experience. Techniques in Coloproctology, 2008, 12, 111-117.	1.8	38
41	Locally injected Infliximab ameliorates murine DSS colitis: Differences in serum and intestinal levels of drug between healthy and colitic mice. Digestive and Liver Disease, 2013, 45, 1017-1021.	0.9	38
42	Use of Infliximab in Particular Clinical Settings: Management Based on Current Evidence. American Journal of Gastroenterology, 2009, 104, 1575-1586.	0.4	37
43	Helicobacter pylori Eradication and Remission of Low-grade Gastric Mucosa-associated Lymphoid Tissue Lymphoma. Journal of Clinical Gastroenterology, 2000, 31, 169-171.	2.2	36
44	Assessment of neurological manifestations in hospitalized patients with COVID-19. European Journal of Neurology, 2020, 27, 2322-2328.	3.3	36
45	Prevalence of factor V Leiden and the G20210A prothrombin-gene mutation in inflammatory bowel disease. Blood Coagulation and Fibrinolysis, 2000, 11, 499-503.	1.0	33
46	Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study. United European Gastroenterology Journal, 2016, 4, 604-613.	3.8	33
47	Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxicillin and either clarithromycin or azithromycin. Alimentary Pharmacology and Therapeutics, 1996, 10, 997-1000.	3.7	32
48	Biological Therapies For Inflammatory Bowel Disease: Research Drives Clinics. Mini-Reviews in Medicinal Chemistry, 2006, 6, 771-784.	2.4	32
49	FOXP3 ⁺ Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNF. http://www.w3.org/1998/Math/MathML id="M1" > < mml:mrow > < mml:mi mathvariant="bold-italic" > ± < /mml:mi > < /mml:mrow > < /mml:math > Agents. BioMed Research International. 2013. 2013. 1-10.	1.9	31
50	Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease. United European Gastroenterology Journal, 2019, 7, 1189-1197.	3.8	31
51	Clinical trial: oral colon-release parnaparin sodium tablets (CB0105 MMX [®]) for active left-sided ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2010, 31, 375-386.	3.7	29
52	Prevention and Treatment of Venous Thromboembolism in Patients with IBD. Inflammatory Bowel Diseases, 2015, 21, 1204-1213.	1.9	28
53	Low-dose omeprazole plus clarithromycin and either tinidazole or amoxicillin for Helicobacter pylori infection.. Alimentary Pharmacology and Therapeutics, 1996, 10, 285-288.	3.7	27
54	Gastric Mucosa-Associated Lymphoid Tissue in Autoimmune Thyroid Diseases. Scandinavian Journal of Gastroenterology, 1997, 32, 869-872.	1.5	27

#	ARTICLE	IF	CITATIONS
55	The Growth of Primary Low-Grade B-Cell Gastric Lymphoma Is Sustained by <i>Helicobacter pylori</i> . <i>Scandinavian Journal of Gastroenterology</i> , 1997, 32, 285-287.	1.5	27
56	Training Programs on Endoscopic Scoring Systems for Inflammatory Bowel Disease Lead to a Significant Increase in Interobserver Agreement Among Community Gastroenterologists. <i>Journal of Crohn's and Colitis</i> , 2016, 11, j181.	1.3	27
57	Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises From a First Meta-Analysis. <i>Transplantation Proceedings</i> , 2016, 48, 402-407.	0.6	26
58	<i>Helicobacter Pylori</i> Eradication Helps Resolve Pyloric and Duodenal Stenosis. <i>Journal of Clinical Gastroenterology</i> , 1996, 23, 157-158.	2.2	26
59	Disappearance of Gastric Mucosa-Associated Lymphoid Tissue in Coeliac Patients after Gluten Withdrawal. <i>Scandinavian Journal of Gastroenterology</i> , 1998, 33, 401-405.	1.5	25
60	Anti-TNF- α Agents in Inflammatory Bowel Disease and Course of COVID-19. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e73-e73.	1.9	25
61	Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab. <i>PLoS ONE</i> , 2017, 12, e0186575.	2.5	23
62	Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2020, 115, 1722-1724.	0.4	21
63	International Consensus on Diverticulosis and Diverticular Disease. Statements from the 3rd International Symposium on Diverticular Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 57-66.	0.9	21
64	The Economic Burden of Diverticular Disease. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, S2-S3.	2.2	19
65	Aortic Stiffening Is an Extraintestinal Manifestation of Inflammatory Bowel Disease: Review of the Literature and Expert Panel Statement. <i>Angiology</i> , 2020, 71, 689-697.	1.8	19
66	Biological therapies for inflammatory bowel disease: controversies and future options. <i>Expert Review of Clinical Pharmacology</i> , 2009, 2, 391-403.	3.1	18
67	A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: Infliximab and surgery. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 421-426.	1.3	18
68	Gut Microbiota: A Key Modulator of Intestinal Healing in Inflammatory Bowel Disease. <i>Digestive Diseases</i> , 2016, 34, 202-209.	1.9	18
69	Primary hyperparathyroidism: acute paranoid psychosis. <i>American Journal of Emergency Medicine</i> , 2003, 21, 250-251.	1.6	17
70	CD40L-Positive Platelets Induce CD40L Expression De Novo in Endothelial Cells: Adding a Loop to Microvascular Inflammation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, e162.	2.4	17
71	Direct effect of infliximab on intestinal mucosa sustains mucosal healing: exploring new mechanisms of action. <i>Digestive and Liver Disease</i> , 2016, 48, 391-398.	0.9	17
72	CT and MRI Evaluations in Crohn's Complications: A Guide for the Radiologist. <i>Academic Radiology</i> , 2022, 29, 1206-1227.	2.5	16

#	ARTICLE	IF	CITATIONS
73	Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure <i>Helicobacter pylori</i> infection. <i>European Journal of Gastroenterology and Hepatology</i> , 1999, 11, 247-250.	1.6	15
74	Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. <i>Digestion</i> , 2017, 96, 166-172.	2.3	15
75	Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2004, 36, 528-532.	0.9	14
76	A review of Magnetic Resonance Enterography classification and quantitative evaluation of active disease in patients with Crohn's disease. <i>Clinical Imaging</i> , 2021, 69, 50-62.	1.5	14
77	One-week therapy for <i>Helicobacter pylori</i> eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxicillin. <i>Alimentary Pharmacology and Therapeutics</i> , 1998, 12, 539-543.	3.7	13
78	PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 826-828.	1.6	13
79	Therapeutic drug monitoring of anti-TNF- α agents in inflammatory bowel diseases. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1107-1117.	3.1	13
80	Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey. <i>International Journal of Clinical Practice</i> , 2021, 75, e14755.	1.7	13
81	Human herpesvirus 8-associated colonic Kaposi's sarcoma during vedolizumab treatment in ulcerative colitis: a case report and review of the literature. <i>BMC Gastroenterology</i> , 2020, 20, 76.	2.0	11
82	<i>Helicobacter pylori</i> eradication down-regulates matrix metalloproteinase-9 expression in chronic gastritis and gastric ulcer. <i>Gastroenterology</i> , 2004, 126, 369-371.	1.3	10
83	Venous Thromboembolism in Patients with Inflammatory Bowel Disease: The Role of Pharmacological Therapy and Surgery. <i>Journal of Clinical Medicine</i> , 2020, 9, 2115.	2.4	10
84	Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID-19. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 902-903.	3.7	9
85	Prognostic performance of the \hat{C} DICA \hat{C} endoscopic classification and the \hat{C} CODA \hat{C} score in predicting clinical outcomes of diverticular disease: an international, multicentre, prospective cohort study. <i>Gut</i> , 2022, 71, 1350-1358.	12.1	9
86	A modern multidisciplinary approach to the treatment of enterocutaneous fistulas in Crohn's disease patients. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 857-865.	3.0	7
87	Thrombopoietin serum levels in patients with inflammatory bowel disease with and without previous thromboembolic events. <i>Hepato-Gastroenterology</i> , 2003, 50, 132-5.	0.5	7
88	Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482211022.	3.2	7
89	Six-day or seven-day regimens with ranitidine bismuth citrate plus high-dose clarithromycin and tinidazole are both effective against <i>Helicobacter pylori</i> infection. <i>Digestive Diseases and Sciences</i> , 1999, 44, 2386-2389.	2.3	6
90	Characterization of mucosal cytokine profile in ulcerative colitis patients under conventional and anti-TNF- α treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1527-1532.	1.6	6

#	ARTICLE	IF	CITATIONS
91	Assessment of Crohn's Disease Activity: Magnetic Resonance Enterography in Comparison with Clinical and Endoscopic Evaluations. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 213-224.	0.9	6
92	What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2016, 7, 387.	1.1	6
93	The "DICA" Endoscopic Classification for Diverticular Disease of the Colon Shows a Significant Interobserver Agreement among Community Endoscopists. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 23-27.	0.9	6
94	Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. <i>Biomedicines</i> , 2022, 10, 843.	3.2	6
95	Variation of the endoscopic pattern of low-grade gastric malt-lymphoma after <i>Helicobacter pylori</i> eradication. <i>Gastrointestinal Endoscopy</i> , 1998, 48, 231-232.	1.0	5
96	Genetic and nutritional predictors of hyperhomocysteinemia in inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2002, 97, 490-491.	0.4	5
97	Intestinal Microbiome Modulation During Coronavirus Disease 2019: Another Chance to Manage the Disease?. <i>Gastroenterology</i> , 2022, 162, 2134.	1.3	5
98	Editorial: The Role of Endoscopy in the Diagnosis and Follow-up of Low-Grade Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Journal of Clinical Gastroenterology</i> , 1997, 25, 496-498.	2.2	5
99	Infliximab does not increase colonic cancer risk associated to murine chronic colitis. <i>World Journal of Gastroenterology</i> , 2016, 22, 9727.	3.3	5
100	When can unfractionated heparin really be useful in the treatment of ulcerative colitis?. <i>Gastroenterology</i> , 2001, 120, 1306-1307.	1.3	4
101	Thrombotic Complications in Inflammatory Bowel Disease: A Multifactorial Etiology. <i>American Journal of Gastroenterology</i> , 2001, 96, 1301-1302.	0.4	4
102	A Case of Hereditary Hemorrhagic Telangiectasia Associated With Crohn's Disease Successfully Treated With Infliximab. <i>American Journal of Gastroenterology</i> , 2010, 105, 1904.	0.4	4
103	Anti-TNF- α -induced psoriasiform lesions in IBD: an abnormal immune activation or a "patchy cutaneous" immune suppression?. <i>Gut</i> , 2014, 63, 699-701.	12.1	4
104	The impact of COVID-19 pandemic on IBD endoscopic procedures in a high-volume IBD Center. <i>Endoscopy International Open</i> , 2020, 08, E980-E984.	1.8	4
105	Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482096874.	3.2	4
106	Endoscopic findings and clinical patterns are not useful for distinguishing low from high grade gastric MALT lymphoma - Reply. <i>Gut</i> , 1997, 41, 577-577.	12.1	3
107	Onset of severe perianal disease in Crohn's disease under treatment with infliximab. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 676-678.	1.9	3
108	Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis. <i>Drug, Healthcare and Patient Safety</i> , 2016, 8, 1.	2.5	3

#	ARTICLE	IF	CITATIONS
109	Biologic therapies in ulcerative colitis: primi inter pares?. <i>Current Drug Targets</i> , 2018, 19, 748-756.	2.1	3
110	Intima-Media Thickness in Inflammatory Bowel Disease Patients: A Still Open Question. <i>American Journal of Gastroenterology</i> , 2008, 103, 490-490.	0.4	2
111	Exacerbation of Crohn's disease as paradoxical effect of infliximab. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 396.	1.3	2
112	Hot Topics in Surgical Management of Acute Diverticulitiss. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 29-34.	0.9	2
113	The DICA Endoscopic Classification for Diverticular Disease of the Colon Shows a Significant Interobserver Agreement among Community Endoscopists: an International Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 39-44.	0.9	2
114	Eradication of <i>Helicobacter pylori</i> as the first step in the treatment of peptic stenosis. <i>Gastrointestinal Endoscopy</i> , 1996, 44, 757.	1.0	1
115	What is the best azithromycin-based therapy for <i>Helicobacter pylori</i> infection?. <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 39, 111-111.	3.0	1
116	Response to Mahadevan and Kane. <i>American Journal of Gastroenterology</i> , 2010, 105, 219-220.	0.4	1
117	Response to Jackson et al.. <i>American Journal of Gastroenterology</i> , 2011, 106, 547-548.	0.4	1
118	342 Retreatment With Infliximab in Inflammatory Bowel Disease: Tolerability and Effectiveness of Different Re-Induction Regimens. <i>Gastroenterology</i> , 2014, 146, S-78-S-79.	1.3	1
119	Acute cytomegalovirus infection as a possible trigger for pulmonary thromboembolism in a patient with steroid-refractory ulcerative colitis. <i>Digestive and Liver Disease</i> , 2014, 46, 290-291.	0.9	1
120	Development and Validation of Predictive Assessment of Complicated Diverticulitis Score. <i>Journal of Personalized Medicine</i> , 2021, 11, 80.	2.5	1
121	Is Cytotoxic-associated Gene A-positive <i>Helicobacter pylori</i> Important?. <i>Journal of Clinical Gastroenterology</i> , 2001, 32, 91-92.	2.2	1
122	Mucosal healing in ulcerative colitis: surveillance or colectomy?. <i>Annals of Gastroenterology</i> , 2013, 26, 355.	0.6	1
123	Orphan patients with inflammatory bowel disease - when we treat beyond evidence. <i>World Journal of Gastroenterology</i> , 2021, 27, 8047-8057.	3.3	1
124	To perform or not to perform liver biopsy: an alternative view. <i>Gut</i> , 2003, 52, 1227-1227.	12.1	0
125	Response to El-Matary. <i>American Journal of Gastroenterology</i> , 2009, 104, 2852-2853.	0.4	0
126	Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: The Picture Is Taking Shape. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 205-206.	4.4	0

#	ARTICLE	IF	CITATIONS
127	How to Face the Advent of SARS-CoV-2 Vaccination in IBD Patients: Another Task for Gastroenterologists. <i>Vaccines</i> , 2021, 9, 248.	4.4	0
128	Thrombotic complications in inflammatory bowel disease: a multifactorial etiology. <i>American Journal of Gastroenterology</i> , 2001, 96, 1301-1302.	0.4	0
129	Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 2677-2682.	0.4	0
130	Genetic and nutritional predictors of hyperhomocysteinemia in inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2002, 97, 490-491.	0.4	0